Provided by Tiger Fintech (Singapore) Pte. Ltd.

Femasys Inc

0.8000
0.0000
Post-market: 0.84990.0499+6.24%19:14 EDT
Volume:395.73K
Turnover:318.06K
Market Cap:21.79M
PE:-0.88
High:0.8200
Open:0.7910
Low:0.7810
Close:0.8000
Loading ...

Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

THOMSON REUTERS
·
27 Mar

Femasys Inc. FY EPS USD -0.85

THOMSON REUTERS
·
27 Mar

Press Release: Femasys Announces Financial Results for Year Ended December 31, 2024, and Provides Corporate Update

Dow Jones
·
27 Mar

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
27 Mar

Femasys Inc : H.c. Wainwright Raises Target Price to $15 From $12

THOMSON REUTERS
·
20 Mar

Femasys Inc. : H.c. Wainwright Raises Target Price to $15 From $12

THOMSON REUTERS
·
19 Mar

Femasys enters partnership with CNY Fertility

TIPRANKS
·
19 Mar

Q1 Virtual Investor Summit: On-Demand Presentations Now Live

ACCESS Newswire
·
19 Mar

Femasys Secures Distribution Partnerships for Commercialization of FemBloc® in Spain

GlobeNewswire
·
18 Mar

Femasys Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
14 Mar

Femasys Announces FemBloc Delivery System Approval in Europe; A Significant Step Towards FemBloc Permanent Birth Control Availability as the First-Ever Non-Surgical Approach

GlobeNewswire
·
13 Mar

Femasys Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
26 Feb

Femasys’s FemBloc: A Promising Investment in Permanent Contraceptive Innovation

TIPRANKS
·
26 Feb

Femasys announces publication of ‘positive’ results from FemBloc trials

TIPRANKS
·
25 Feb

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results From Fembloc® Permanent Birth Control Clinical Trials

THOMSON REUTERS
·
25 Feb

Femasys Announces Peer-Reviewed Publication of Positive Safety and Efficacy Results from FemBloc® Permanent Birth Control Clinical Trials

GlobeNewswire
·
25 Feb

Femasys Price Target Maintained With a $12.00/Share by HC Wainwright & Co.

Dow Jones
·
12 Feb

Femasys Announces UK Regulatory Approvals for Femaseed® for Female Infertility Treatment and Two Diagnostic Devices

THOMSON REUTERS
·
11 Feb

Femasys announces Israeli regulatory approvals for FemaSeed treatment

TIPRANKS
·
04 Feb

Femasys -Israeli Regulatory Approvals for Femaseed for Female Infertility Treatment and Two Diagnostic Devices

THOMSON REUTERS
·
04 Feb